Bristol-Myers signs $380 million CAR-T therapy supply agreement with Cellares (NYSE: BMY)

Bristol-Myers Squibb (NYSE: BMY) announced on Monday a $380 million agreement with contract manufacturer Cellares to produce CAR T-cell therapies.

Bristol-Myers Squibb (BMY) will leverage Cellares’ proprietary cell therapy manufacturing platform Cell as part of global capacity reservation and supply agreement

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top